Trelegy Ellipta approved as first once-daily single inhaler triple therapy for appropriate US patients with COPD

The US Food and Drug Administration has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.

The product has been developed by UK pharma major GlaxoSmithKline and its US partner Innoviva, and will be marketed under the name Trelegy Ellipta. It is not indicated for relief of acute bronchospasm or the treatment of asthma.